finance News

Aqilion has strengthened its pipeline with an innovative development program in the field of chronic inflammation. With this acquisition, Aqilion is taking over all rights to the program, now under the name Regulus, from LEO Pharma. The project is ready for clinical trials and Aqilion plans to begin clinical development in...
NEW YORK and BASEL, Switzerland – Aruvant Sciences (“Aruvant”), a private company focused on developing gene therapies for rare diseases, announced it has added eleven scientists to its manufacturing, preclinical and clinical teams, a major milestone in the company’s strategy to build a beginning-to-end internal-external supply model led by its pioneering cell and...
The UK Competition and Markets Authority has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion). As a result, the acquisition is expected to close on 21 July 2021. Following closing, the new AstraZeneca shares issued to Alexion shareholders will be admitted to listing on the premium listing segment of...
AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including...
SOUTH SAN FRANCISCO, Calif. – Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company has joined the Rare Disease Company Coalition. The coalition represents an alliance of...
SAN DIEGO – Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced it has acquired global rights to ASP3652, a novel oral peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor from Astellas Pharma Inc. ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated...
ZURICH and NEWPORT BEACH, Calif. – BC Platforms (BCP), a global leader in healthcare data management, analytics, and access and CureDuchenne, a leading global non-profit organisation focused on finding and funding a cure for Duchenne muscular dystrophy, today announced a new collaboration. As part of the collaboration, CureDuchenne has integrated BCP’s Discovery and Research...
MINNEAPOLIS – Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to include supply chain services in support of the upcoming commercial launch of Libmeldy™ (autologous...
GUANGZHOU, China & LONDON – Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara® (ustekinumab), in the United States (US). BAT2206 is currently in a...